Consensus Enliven Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
22.57 ^USD	+0.13%		-5.72%	+63.08%

05-20	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing	MT
05-14	Enliven Therapeutics Q1 Loss Narrows	MT

03b7211.5lWeWoIGZcoU6pS-id56apSLeGwA1Qs-dMH_3bgvJ_I.qTPLPupUSP0lq9rf6LRPW__KNi5q5mFELq-1goFOUpeUL-czu1dIoHCt0Q~b06e99ee2bc865b2bf2b7f58cf37acd4

Mizuho Securities Initiates Enliven Therapeutics With Buy Rating, Price Target is $34	04-09	MT
Jefferies Initiates Enliven Therapeutics at Buy With $27 Price Target	23-03-29	MT
TD Cowen Starts Enliven Therapeutics at Outperform	23-03-03	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.57 USD

Average target price

34.67 USD

Spread / Average Target

+53.60%

High Price Target

38 USD

Spread / Highest target

+68.37%

Low Price Target

32 USD

Spread / Lowest Target

+41.78%